Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
Minerva Neurosciences, Inc (NERV) Debt to Capital Ratio data is not available for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-293.42M |
|
-- |
|
-- |
|
$15.10M |
|
$-15.10M |
|
$-278.32M |
|
$-293.42M |
|
$-293.42M |
|
$-293.42M |
|
$-293.42M |
|
$-293.42M |
|
$-293.42M |
|
$-15.10M |
|
$-15.10M |
|
8.46M |
|
8.46M |
|
$-34.67 |
|
$-34.67 |
|
| Balance Sheet Financials | |
$83.10M |
|
-- |
|
$14.87M |
|
$97.97M |
|
$2.29M |
|
-- |
|
$236.43M |
|
$238.72M |
|
$-140.75M |
|
$-155.62M |
|
$-140.75M |
|
43.27M |
|
| Cash Flow Statement Financials | |
$-13.51M |
|
-- |
|
$74.45M |
|
$21.46M |
|
$82.40M |
|
$60.94M |
|
$1.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
36.28 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-13.51M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
208.47% |
|
188.55% |
|
-299.51% |
|
208.47% |
|
$-3.25 |
|
$-1.60 |
|
$-1.60 |
|